real-world analysis of the most study: factors impacting progression to mf in patients with et
Published 6 months ago • 127 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
2:05
minimal clinically important difference in patient-reported mf-associated outcomes: manifest arm 3
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
5:46
determination: results & implications in clinical practice
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
3:40
results of a study evaluating the predictive power of fish markers for pfs in al amyloidosis
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
4:54
beakertv | meet brenda montgomery, msl at biomea fusion
-
3:22
emerging aml treatments: what is menin inhibitor therapy?
-
9:25
mgus diagnosis: a step-by-step approach
-
0:55
a pooled analysis to determine the optimal ki-67 index cut-off point for predicting outcomes in mcl
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
4:12
insight-mm: real-world patterns of patient characteristics
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
1:21
the correlation between jak2v617f molecular response and efs in patients with early pv
-
3:23
molecular characteristics associated with increased risk of disease progression in smm
-
1:16
insights into an oncology simulation model being used to evaluate treatment regimens in hl
-
4:19
commands study: efficacy & safety results and biomarker analysis
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
6:50
an overview of the immunotherapy landscape in aml: antibodies, bispecifics, & car-t
-
2:41
an overview of the latest advances in hematology